Skip to main content
. 2020 Nov 13;10:541262. doi: 10.3389/fonc.2020.541262

Figure 1.

Figure 1

MTA1 is a prognosis factor of luminal-b breast cancer. (1) mRNA level of MTA1-3 in breast cancer tissues and adjacent normal tissues from TCGA data (A, E, I). (2) mRNA level of MTA1-3 in breast cancer tissues (TNBC, Her-2 type, Luminal_A and luminal-b) and adjacent normal tissues from TCGA data (B, F, J). (3) mRNA level of MTA1-3 in different clinical stages breast cancer tissues and adjacent normal tissues from TCGA data (C, G, K). (4) mRNA level of MTA1-3 in different clinical stages luminal-b breast cancer tissues and adjacent normal tissues from TCGA data (D, H, L). (5) IHC of MTA1 in luminal-b breast cancer tissue sections, which showed higher MTA1 expression with higher clinical stage (p<0.01) (M, N). (6) IHC showed the overall survival in high and low expression of MTA1 breast cancer groups, which revealed higher expression of MTA1 accompanied with worse prognosis (p=0.0289) (M, N).